Latest News - Pfizer
Top Corporates Hub
Pfizer
Pfizer’s HYMPAVZI Pediatric Approval Deepens Rare Disease Growth Story
10.06.2026 01:16
U.S. FDA expands approval of HYMPAVZI for pediatric hemophilia A and B patients. Label now includes children as young as six, with and without inhibitors. First subcutaneous non factor therapy approved for hemophilia B patients ages 6 to 11. Development is material for Pfizer’s (NYSE:PFE) hemophilia segment and rare disease portfolio. For Pfizer, rare diseases sit alongside vaccines, oncology, and other therapeutics as core parts of its business mix. The broader hemophilia treatment space...
GSK Buys Nuvalent for $10.6 Billion in Major Cancer Push
09.06.2026 09:01
(Bloomberg) -- GSK Plc agreed to buy Nuvalent Inc. for $10.6 billion, securing a US biotech firm developing treatments for lung cancer as part of the British pharmaceutical company’s effort to rebuild its oncology franchise.Most Read from BloombergHouse Republican Says Hegseth’s D-Day Remarks ‘Inappropriate’LA Mayor Race Flips as Socialist Beats Reality TV Star PrattTrump’s $100,000 H-1B Visa Application Fee Rejected by JudgeTrump Says He, Not Congress, Is in Charge of Kennedy Center in Reversal
Pfizer licenses Chai Discovery AI platform for drug discovery
05.06.2026 13:41
Pfizer will gain early access to Chai-3, a previously undisclosed model that doubles the antibody design success rate of its predecessor
Investors are taking profits ahead of SpaceX IPO, says Capital Wealth's Kevin Simpson
05.06.2026 13:25
The CNBC Halftime Report Investing Committee discusses the latest moves in the market after the May jobs report and a sell-off in tech stocks.
AbCellera Appoints Dr. Victor Sandor to its Board of Directors
05.06.2026 13:00
VANCOUVER, British Columbia, June 05, 2026--AbCellera Appoints Dr. Victor Sandor to its Board of Directors
Pfizer signs licence agreement with Chai for AI drug discovery
05.06.2026 10:17
According to the agreement, Pfizer will become one of the first pharmaceutical companies to access Chai’s newly revealed Chai-3 model.
Pfizer Oncology Data At ASCO 2026 Reshapes Long Term Growth Story
03.06.2026 02:07
Pfizer (NYSE:PFE) reported breakthrough Phase 3 results for its BRAFTOVI combination in first-line metastatic colorectal cancer and TALZENNA combination in metastatic hormone-sensitive prostate cancer, presented at ASCO 2026. The BREAKWATER trial of BRAFTOVI with cetuximab and FOLFIRI in BRAF V600E mutated metastatic colorectal cancer showed strong efficacy signals in progression-free and overall survival. The TALAPRO-3 study of TALZENNA with XTANDI in hormone-sensitive prostate cancer...
Is Pfizer Inc. (PFE) Expanding Its Cancer Pipeline Through a Landmark Innovent Partnership?
02.06.2026 14:11
We recently compiled a list of the 11 Most Undervalued Pharma Stocks to Invest In. Pfizer Inc. (NYSE:PFE) is one of the most undervalued stocks on this list. TheFly reported on May 27 that PFE and Innovent Biologics announced a global strategic licensing and collaboration agreement covering the research and development of 12 early-stage oncology programs, including […]
Why Pfizer’s Current Price May Be Too Cheap to Ignore
02.06.2026 14:03
Pfizer (NYSE:PFE) is one of those names where the headline narrative (COVID hangover, patent cliff) keeps overshadowing what is actually a defensive cash machine trading at a single-digit forward multiple. After running the numbers, my view leans constructive, and the 24/7 Wall St. price target reflects that. PFE stock trades at $26.18, and our 24/7 ... Why Pfizer’s Current Price May Be Too Cheap to Ignore
Revolution Medicines: More Landmark Data Doesn't Dispel Doubts Around Valuation
02.06.2026 13:31
Revolution Medicines is rated a Hold due to valuation concerns, uncertain acquisition prospects, and solo commercialization. Read more on RVMD stock here.
Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock
02.06.2026 13:00
Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.
Pfizer CEO Albert Bourla on the company's obesity drug pipeline
02.06.2026 08:18
Pfizer CEO Albert Bourla joins 'Squawk Box' to discuss the company's obesity drug pipeline.
Zoetis: Potential Deep Value Play With 60%+ Upside Potential Dividend Investors Should Watch
02.06.2026 07:45
Zoetis stock fell 50% amid inflation and demand worries. Click here to read more on the stock's dividend safety, valuation, upside potential, and risks.
Pfizer CEO Albert Bourla on the company's oncology focus
02.06.2026 07:10
Pfizer CEO Albert Bourla joins 'Squawk Box' to discuss the company's recent announcement about the lung cancer drug that has shown promising results on slowing the progression of the disease.
How S&P 500 Giant Pfizer Is Tackling Hard-To-Treat Cancers
31.05.2026 12:00
Pfizer said Sunday its Braftovi-tied regimen nearly doubled the length of time colon cancer patients lived without getting sicker.
Growing US reliance on Chinese biotechs prompts national security fears
31.05.2026 12:00
Lawmakers and some investors are warning about the growing reliance of US pharmaceutical companies on China, raising the prospect of national...
Pfizer’s BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer
31.05.2026 12:00
NEW YORK, May 31, 2026--Pfizer Inc. (NYSE: PFE) today announced detailed progression-free and overall survival results from Cohort 3, a randomized cohort of the Phase 3 BREAKWATER trial, evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and FOLFIRI (fluorouracil, leucovorin, and irinotecan) versus FOLFIRI with or without bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC) with a BRAF V600E mutation. These results will be pre
A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China
31.05.2026 08:00
An experimental lung cancer drug from Akeso and Summit Therapeutics reduced the risk of death by 34% in a late-stage trial, according to data released Sunday.
Pfizer's $10.5 Billion Oncology Bet Sends Innovent Shares Surging
29.05.2026 18:40
Pfizer and Innovent strike a global cancer-drug partnership as Chinese biotech licensing momentum accelerates.
Pfizer Expands Oncology Pipeline in $10.5B Innovent Deal
29.05.2026 13:45
Pfizer and Innovent signed a global oncology deal worth up to $10.5 billion.